Merit Medical (MMSI) Q4 2025 earnings review
Record Margins Mask a Decelerating 2026 Growth Outlook
Merit Medical closed 2025 with an excellent display of operational leverage. While top-line revenue grew a solid 11% to $393.9M, non-GAAP operating margins surged to 21.0%—a 140 basis-point improvement year-over-year. The Cardiac Intervention segment was the star, up 23%. However, the underlying narrative reveals stress points: the OEM segment is violently reversing, dropping 15% YoY. Management's FY26 guidance projects top-line and bottom-line growth decelerating to mid-single digits (6-8% revenue, 5-8% EPS), indicating that the easy comps and initial boosts from recent M&A are fading.
🐂 Bull Case
Merit successfully pushed non-GAAP operating margins to 21.0% and non-GAAP gross margins to 54.5% in Q4. Their Continued Growth Initiatives (CGI) program is clearly offsetting the massive tariff headwinds discussed earlier in the year.
Free cash flow reached $215.7M for FY25, up 16% YoY. This gives new CEO Martha Aronson ample firepower to continue the company's successful strategy of tuck-in acquisitions.
🐻 Bear Case
The OEM division fell 15% YoY in Q4 to $48.1M. This is a severe deterioration from the +20% growth seen in Q1 and reflects ongoing macro softness in China and international markets.
Guidance for 2026 implies 5-8% EPS growth and 6-8% revenue growth. This is a noticeable step-down from the double-digit growth investors enjoyed throughout 2025.
⚖️ Verdict: ⚪
Neutral. The operational execution is flawless, but the forward-looking deceleration in growth and the collapse in the OEM segment cap the upside. The stock is shifting from a high-growth medtech play to a margin-expansion/cash-flow story.
Key Themes
Cardiac Intervention Accelerating
The Cardiac Intervention segment remains the primary growth engine, accelerating 23% YoY to $117.2M in Q4. This validates the strategy of creating focused sales groups following the Cook Medical lead management portfolio acquisition, driving higher penetration in EP and CRM products.
CGI Program Driving Stable Margin Expansion
Despite absorbing an estimated $26M+ in tariff-related COGS headwinds (largely centered on China, as disclosed in Q1), the Continued Growth Initiatives (CGI) program is working. Non-GAAP gross margins expanded 100 bps YoY in Q4, proving Merit has legitimate pricing power and supply chain agility.
Endoscopy Segment Integration Pacing Well
Endoscopy revenue grew 15% YoY to $20.1M in Q4. The integration of the C2 CryoBalloon assets (acquired from Pentax in Nov 2025) and EndoGastric Solutions is providing the specialized sales force with a broader portfolio to drive cross-selling.
OEM Segment Reversing on Macro Weakness
The OEM segment is a glaring red flag, reversing from mid-single-digit growth earlier in the year to a 15% YoY contraction in Q4. Management previously attributed international OEM weakness to China's macro environment and retaliatory tariffs. This suggests the international headwind has worsened significantly.
Decelerating Guidance Contradicts 'Strongest Position Ever' Narrative
Management boasts of operational excellence, yet FY26 guidance for 6-8% revenue growth contradicts the narrative of an unstoppable growth engine. FY25 delivered 12% top-line and 11% non-GAAP EPS growth. The deceleration implies Merit is struggling to find organic volume growth to replace the tailwinds of recent acquisitions.
WRAPSODY CIE Execution Risk
While not detailed in the Q4 release, a major Q2 misstep (filing for an APC assignment instead of a TPT add-on payment) delayed U.S. outpatient reimbursement for the WRAPSODY device to January 2026. The decelerating FY26 guidance suggests management may have dialed back expectations for WRAPSODY's initial outpatient ramp.
Other KPIs
Accelerating. Up 16% YoY. This cash generation profile comfortably covers the company's strategic M&A ambitions (like Biolife and C2 CryoBalloon) without stretching the balance sheet. Available borrowing capacity remains robust at ~$697M.
Stable. Grew 15% YoY as reported (13% constant currency). This remains Merit's largest sub-segment, driven by sustained demand for core products like Embosphere Microspheres and the SwiftNinja steerable microcatheter.
Guidance
Decelerating. Represents 6-8% YoY growth on a reported basis (5-7% constant currency). This is a noticeable slowdown from the 11.8% reported growth achieved in FY25, reflecting tougher comps and the lapping of M&A inorganic contributions.
Decelerating. Implies 5-8% YoY growth, down from the 11% growth posted in FY25. This suggests that while margin expansion (via CGI) is holding steady, the lack of explosive top-line growth is capping bottom-line acceleration.
Key Questions
OEM Collapse
The OEM segment violently reversed to a 15% YoY decline in Q4. How much of this is driven by the macro environment in China versus lost contracts, and what is assumed for OEM in the FY26 6-8% growth guidance?
WRAPSODY Revenue Expectations
Given the reimbursement filing error disclosed earlier in 2025 that delayed outpatient TPT to early 2026, what specific revenue contribution from WRAPSODY is baked into the new FY26 guidance?
Tariff Mitigation Run-Rate
You previously outlined a $26M+ tariff headwind for 2025 with plans to mitigate 45% of it by 2026 through the CGI program. Are those mitigation savings fully reflected in the FY26 EPS guide of $4.01-$4.15, or is there further upside?
M&A Strategy Post-Transition
With Martha Aronson now fully at the helm and generating $215M in free cash flow, will the M&A strategy shift from smaller tuck-ins (like Biolife and C2) to larger, more transformative deals to combat organic deceleration?